<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853996</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-01116</org_study_id>
    <secondary_id>10588</secondary_id>
    <secondary_id>UW105-6-01</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <nct_id>NCT00853996</nct_id>
    <nct_alias>NCT00855751</nct_alias>
  </id_info>
  <brief_title>Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer</brief_title>
  <official_title>Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well acolbifene works in preventing cancer in
      premenopausal women at high risk of breast cancer. Chemoprevention is the use of certain
      drugs to keep cancer from forming. The use of acolbifene may stop cancer from growing or
      coming back.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the effect of six months of acolbifene 20 mg/day on Ki-67 in high risk
      premenopausal women with baseline hyperplasia +/- atypia and Ki-67 positivity of &gt;= 2%..

      SECONDARY OBJECTIVES:

      I. To determine the effect of six months of acolbifene 20 mg/day on mammographic breast
      density in high risk premenopausal women.

      II. To determine the effect of six months of acolbifene 20 mg/day on serum levels of
      follicular phase bioavailable estradiol, and luteal phase progesterone, testosterone, and
      fasting IGF-1/IGFBP-3.

      III. To determine the effect of six months of acolbifene 20 mg/day on epithelial cell
      cytomorphology and molecular markers such as ER, PgR, and pS2.

      IV. To determine the effect of six months of acolbifene on markers of cardiovascular risk
      (C-reactive protein, functional AntiThrombin III, and fasting lipid profile) and bone
      turnover markers associated with bone mineral density gain or loss (serum osteocalcin and
      N-telopeptide crosslinks).

      V. To assess any increase in reported hot flashes, menstrual cycle irregularities, pelvic
      pain, musculoskeletal complaints, and fatigue from baseline.

      OUTLINE:

      Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of
      unacceptable toxicity.

      Patients undergo symptom assessment (hot flashes, menstrual abnormalities, pelvic pain,
      muscle and joint pain, and fatigue) at baseline, 6-8 weeks, monthly for 6 months, and then at
      2 weeks after completion of study treatment.

      Patients undergo random periareolar fine needle aspiration between days 1-10 of menstrual
      cycle at baseline and at 6 months. Patients also undergo blood sample collection between days
      1-10 and days 20-24 of menstrual cycle at baseline and at 6 months. Samples taken between
      days 1-10 of menstrual cycle are analyzed for Ki-67 expression, cytomorphology, molecular
      markers (estrogen receptor, progesterone receptor, and pS2 expression), and bioavailable
      estradiol levels. Samples taken between days 20-24 of menstrual cycle are analyzed for
      progesterone, testosterone, IGF-1, IGFBP-3, lipid profile, bone-turnover markers (osteocalcin
      and N-telopeptide crosslinks), C-reactive protein, and functional antithrombin III.

      After completion of study treatment, patients are followed at 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mammographic Breast Density</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in mammographic density from baseline to 6 months, The Percent Breast Density is estimated using the Cumulus computer-assisted program to define a region that is at greater density than the remainder of the breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Estradiol Concentration</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in serum concentration of estradiol from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Concentration of Bioavailable Estradiol</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in serum concentration of bioavailable estradiol (adjusted for concentration of Sex Hormone Binding Globulin), from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Concentration of Testosterone</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in serum concentration of Testosterone from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reports of Hot Flashes as Assessed by the Loprinzi Hot Flash Scoring System</measure>
    <time_frame>Baseline to up to 2 weeks post-treatment</time_frame>
    <description>Problems with hot flashes were assessed by average number per day and intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reports of Muscle/Joint Complaints as Assessed by the Validated HAQ II Questionnaire</measure>
    <time_frame>Baseline to up to 2 weeks post-treatment</time_frame>
    <description>The Health Assessment Questionnaire II (HAQ-II) measures interference in daily activities from arthralgias and joint pain. Range 0 - 4. A higher score indicates greater (i.e., &quot;worse&quot;) interference.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Prevention (acolbifene hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acolbifene hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Prevention (acolbifene hydrochloride)</arm_group_label>
    <other_name>EM-652.HCL</other_name>
    <other_name>SCH 57068.HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gail risk &gt;= 1.7% and/or relative risk &gt;= 3 times that for 5-year age group

          -  Premenopausal

          -  More than 6 months since initiating or discontinuing oral contraceptives

          -  At increased risk for breast cancer, as indicated by &gt;= 1 of the following risk
             factors:

          -  BRCA1/2 mutation characterized as deleterious or of uncertain significance

          -  Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in
             situ

          -  Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia

          -  Family history consistent with hereditary breast cancer, as indicated by 1 of the
             following criteria:

               -  &gt;= 4 relatives with breast cancer

               -  &gt;= 2 relatives diagnosed with breast cancer at â‰¤ 50 years of age

               -  Breast and ovarian cancer diagnosed in same relative

          -  No suspicion for breast cancer on baseline mammogram performed between days 1-10 of
             menstrual cycle within 3 months prior to screening baseline RPFNA

          -  Exhibits hyperplasia with or without atypia (Masood score &gt;= 14) with &gt;= 500 cells AND
             Ki-67 positivity &gt;= 2% by RPFNA performed within 6 months prior to initiation of study
             drug

          -  Estimated visual mammographic breast density category &gt;= 5% on mammogram performed
             within 6 months prior to initiation of study drug

          -  Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen
             oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic
             profile and blood count within normal limits

          -  Absolute granulocyte count &gt; 1,000/mm^3

          -  Platelets &gt; 100,000/mm^3

          -  Hemoglobin &gt; 10 g/dL

          -  Bilirubin &lt; 2.0 mg/dL

          -  AST &lt; 2 times upper limit of normal (ULN)

          -  Albumin &gt; 3.0 g/dL

          -  Creatinine &lt; 1.5 mg/dL

          -  Alkaline phosphatase &lt; 2 times ULN

          -  Concurrent hormonal contraceptives allowed provided patient remains on the same
             hormonal regimen from 3 months prior to baseline aspiration until the completion of
             study treatment

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone
             health (1,200 mg calcium and 800 IU vitamin D daily)

          -  Negative pregnancy test prior to receiving study agent

        Exclusion Criteria

          -  pregnant or nursing

          -  nursing within the past 6 months

          -  Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)

          -  History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or
             hot flashes

          -  History of deep venous thrombosis

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to the study agent

          -  Other condition or concurrent illness that, in the opinion of the investigator, would
             make the patient a poor candidate for RPFNA

          -  Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole,
             exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen
             citrate, raloxifene, or arzoxifene hydrochloride)

          -  Other concurrent chemopreventive agents

          -  Concurrent anticoagulants

          -  Other concurrent investigational agents

          -  Bilateral breast implants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Fabian</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>January 23, 2017</results_first_submitted>
  <results_first_submitted_qc>January 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2017</results_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data will not be shared; only summary assessments.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prevention (Acolbifene Hydrochloride)</title>
          <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prevention (Acolbifene Hydrochloride)</title>
          <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>5-Year Gail Risk</title>
          <description>Projected risk of a women developing breast cancer within the next 5 years, as calculated using the Gail Risk Model.</description>
          <units>Percent risk of developing breast cancer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age First Live Birth</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months</title>
        <description>Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months</title>
          <description>Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.</description>
          <units>percentage of positive cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-20.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons since this was primary endpoint. A priori threshold for statistical significance was set at &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mammographic Breast Density</title>
        <description>Change in mammographic density from baseline to 6 months, The Percent Breast Density is estimated using the Cumulus computer-assisted program to define a region that is at greater density than the remainder of the breast.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>One subject was without a digital file due to technical reasons. Thus, only 24 subjects were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mammographic Breast Density</title>
          <description>Change in mammographic density from baseline to 6 months, The Percent Breast Density is estimated using the Cumulus computer-assisted program to define a region that is at greater density than the remainder of the breast.</description>
          <population>One subject was without a digital file due to technical reasons. Thus, only 24 subjects were evaluated.</population>
          <units>percentage of area at increased density</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" lower_limit="-31.4" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance was set at &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Estradiol Concentration</title>
        <description>Change in serum concentration of estradiol from baseline to 6 months</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Estradiol Concentration</title>
          <description>Change in serum concentration of estradiol from baseline to 6 months</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance was set at &lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Concentration of Bioavailable Estradiol</title>
        <description>Change in serum concentration of bioavailable estradiol (adjusted for concentration of Sex Hormone Binding Globulin), from baseline to 6 months</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Bioavailable Estradiol</title>
          <description>Change in serum concentration of bioavailable estradiol (adjusted for concentration of Sex Hormone Binding Globulin), from baseline to 6 months</description>
          <units>pM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance was set at &lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Concentration of Testosterone</title>
        <description>Change in serum concentration of Testosterone from baseline to 6 months</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Concentration of Testosterone</title>
          <description>Change in serum concentration of Testosterone from baseline to 6 months</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance set at 0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reports of Hot Flashes as Assessed by the Loprinzi Hot Flash Scoring System</title>
        <description>Problems with hot flashes were assessed by average number per day and intensity.</description>
        <time_frame>Baseline to up to 2 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Reports of Hot Flashes as Assessed by the Loprinzi Hot Flash Scoring System</title>
          <description>Problems with hot flashes were assessed by average number per day and intensity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Increase in hot flash frequency and/or severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change in hot flash frequency and/or severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Decrease in hot flash frequency and/or severity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reports of Muscle/Joint Complaints as Assessed by the Validated HAQ II Questionnaire</title>
        <description>The Health Assessment Questionnaire II (HAQ-II) measures interference in daily activities from arthralgias and joint pain. Range 0 - 4. A higher score indicates greater (i.e., &quot;worse&quot;) interference.</description>
        <time_frame>Baseline to up to 2 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Acolbifene Hydrochloride)</title>
            <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Reports of Muscle/Joint Complaints as Assessed by the Validated HAQ II Questionnaire</title>
          <description>The Health Assessment Questionnaire II (HAQ-II) measures interference in daily activities from arthralgias and joint pain. Range 0 - 4. A higher score indicates greater (i.e., &quot;worse&quot;) interference.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Increase in HAQ score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change in HAQ score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Decrease in HAQ score</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of study agent, through 2 weeks following the planned 6 month duration of study agent.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevention (Acolbifene Hydrochloride)</title>
          <description>Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
acolbifene hydrochloride: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intermittent diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <description>At night 3 days during menses</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Worsening Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold or allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Shingles (left flank)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Viral sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cold sores</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bilateral leg cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Finger joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bilateral ankle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle cramp</sub_title>
                <description>Great right toe</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle soreness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Stiffness in left foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe mood swings</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal PAP smear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Amenorrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cervical laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Irregular prolonged menses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intercourse pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Right ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heavy bleeding with menses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Secondary to GERD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Palpable right breast mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acne (scalp and neck)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce F. Kimler Ph.D</name_or_title>
      <organization>University of Kansas Mecical Center</organization>
      <phone>913-588-4523</phone>
      <email>bkimler@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

